SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Isotechnika
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: schzammm who started this subject5/21/2003 1:21:03 PM
From: teevee  Read Replies (2) of 285
 
Comments on AGM....I'm glad to see some clarification on timing-namely sometime in the first half of 2004 for the start of Phase IIb/III and timing for commercialization estimated "sometime between late 2006 and 2008. I was also impressed by managements' sensitivity to shareholder concerns, backing off on the restricted stock plan, even though they purportedly had enough proxies for approval. Another noteworthy comment was that Roche is busy with 50 people gearing up for production of the commercial version of ISAtx247 in "tonne quantities" prior to initiating the phase IIb/III renal trial. I interpret that to indicate ISAtx247 will be commercially available immediately IF the drug receives FDA "fast track" approval.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News